Final analysis of key secondary endpoint OS in 446 patients with mCRPC: enzalutamide plus radium-223 improved OS vs enzalutamide alone (median 38.2 vs 32.6 months; HR 0.76); grade 3 or higher adverse events rose from 57.6% to 69.3%.
RCTn = 446
Gillessen et al. Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer